Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial.
Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III clinical trial investigated the long-term prognosis of 226 postmenopausal women with ER-positive, HER2-negative early breast cancer based on their response to neoadjuvant endocrine therapy and multigene assay results. The study found that in patients with a high Recurrence Score, overall survival was significantly lower with endocrine therapy alone compared to combined chemoendocrine therapy (p = 0.037).
Key findings
- In the high Recurrence Score group, OS was significantly lower with ET alone compared to CT + ET (p = 0.037).
- Among RS high patients achieving CR + PR, no significant OS difference was found between CT + ET and ET alone (p = 0.25).
- Clinical responses to neoadjuvant endocrine treatment were CR in 1.8%, PR in 50%, and SD in 48.2% of patients.
Why it matters
Understanding the relationship between multigene assay results and treatment response can help clinicians make more informed decisions regarding the necessity of chemotherapy in managing postmenopausal ER-positive, HER2-negative breast cancer.
What to keep in mind
The study may have been underpowered to detect meaningful differences due to a limited number of events.